FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A prospective comparative study of pre-op chemoradiotherapy followed by surgery versus upfront surgery followed by adjuvant chemoradiotherapy in locally advanced borderline resectable oral cavity cancer. PMID 40616538 · J Cancer Res Ther · 2025-Apr-01 The study is a randomized trial in oncology with a drug intervention, but the provided metadata does not confirm it as a Phase III or Phase II/III trial. Furthermore, the reported primary endpoints are pathological and surgical outcomes, not a time-to-event efficacy endpoint like OS or DFS, which are required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions. PMID 40333232 · Vaccines (Basel) · 2025-Apr-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical Trial Notifications Triggered by Artificial Intelligence-Detected Cancer Progression: A Randomized Trial. PMID 40257799 · JAMA Netw Open · 2025-Apr-01 The study is a randomized trial in human oncology with a drug intervention (clinical trials as the intervention), but it lacks a time-to-event efficacy endpoint and does not explicitly test a drug intervention in the arms. The primary outcome is trial enrollment rate, not OS/PFS/DFS/EFS/RFS/TTP or any other time-to-event measure. No Kaplan-Meier curves or hazard ratios are reported. The study is not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention with time-to-event endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer. PMID 40106307 · Cancer · 2025-Apr-01 The record describes a secondary subgroup analysis of individual participant-level data from the TITAN trial, investigating heterogeneous treatment effects based on tumor burden. While it analyzes data from a Phase III randomized trial with drug intervention and time-to-event endpoints, it is not the original formal-result report of the trial's primary efficacy analysis. It is a post-hoc or subgroup analysis focused on effect modification, not the primary or key secondary result report of the trial itself. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. PMID 40048197 · JAMA Ophthalmol · 2025-Apr-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial. PMID 40048178 · JAMA Ophthalmol · 2025-Apr-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Lung Cancer Surveillance for Patients With Head and Neck Cancer. PMID 40048159 · JAMA Otolaryngol Head Neck Surg · 2025-Apr-01 The record is for a randomized trial in head and neck cancer with overall survival and disease-free survival as secondary outcomes, but it does not involve a drug-containing intervention (comparing imaging modalities). The trial phase is not explicitly stated in the provided metadata, so it cannot be confirmed as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer. PMID 40015915 · J Nucl Med · 2025-Apr-01 The report is a secondary analysis of FDG-PET parameters as prognostic factors from within a phase II/III randomized trial. While the trial itself is randomized and phase III with time-to-event endpoints, the specific analysis presented lacks evidence of a drug-containing intervention (it compares radiotherapy dose strategies) and is not the primary efficacy report of the trial. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysis. PMID 39992106 · Int J Surg · 2025-Apr-01 The record is from a Phase III randomized trial with time-to-event endpoints, but the intervention is purely surgical (lymphadenectomy). There is no drug-containing intervention, which is a required criterion for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial. PMID 39946142 · JAMA Oncol · 2025-Apr-01 The record is a subgroup/biomarker analysis of a randomized trial with drug intervention and time-to-event endpoints, but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and the primary focus is on TILs subgroup effects, not the overall trial primary efficacy result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An updated systematic review, meta-analysis, and trial sequential analysis of the efficacy and safety of en bloc transurethral resection vs. conventional transurethral resection for nonmuscle-invasive bladder tumor. PMID 39927777 · Int J Surg · 2025-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial. PMID 39918552 · Clin Cancer Res · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial. PMID 39913118 · JAMA Oncol · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort. PMID 39908003 · Clin Cancer Res · 2025-Apr-01 The study meets criteria for oncology, human, randomized, original report with time-to-event analysis. However, it is excluded because the intervention is non-drug-only (radiotherapy), lacking a drug-containing intervention as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study. PMID 39814441 · J Rheumatol · 2025-Apr-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bioequivalence of Preservative-Free and Preserved Omidenepag Isopropyl 0.002% Ophthalmic Solutions in Patients With Primary Open Angle Glaucoma or Ocular Hypertension: Phase 3 DAISY Study. PMID 39750078 · J Glaucoma · 2025-Apr-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial. PMID 39739622 · Int J Cancer · 2025-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial. PMID 39686540 · Int J Cancer · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. PMID 39676239 · J Acquir Immune Defic Syndr · 2025-Apr-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results. PMID 39668671 · Melanoma Res · 2025-Apr-01 The record is a systematic scoping review of PRO reporting in trials, not an original trial report with primary/key secondary time-to-event efficacy results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Nab-Paclitaxel-Treated Unresectable or Recurrent Pancreatic Cancer. PMID 39626189 · Pancreas · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial. PMID 39615657 · Int J Radiat Oncol Biol Phys · 2025-Apr-01 The study is a randomized, human, oncology trial reporting time-to-event efficacy endpoints (PFS, OS). However, it is excluded because the intervention does not include a drug-containing arm (both arms receive identical temozolomide; the comparison is of radiation guidelines, not a drug) and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR. PMID 39612953 · Int J Radiat Oncol Biol Phys · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. PMID 39455063 · J Am Soc Nephrol · 2025-Apr-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate. PMID 39331638 · Rheumatology (Oxford) · 2025-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluating Equity in Clinical Trial Accessibility: An Analysis of Demographic, Socioeconomic, and Educational Disparities in Irritable Bowel Syndrome Drug Trials. PMID 39315667 · Am J Gastroenterol · 2025-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. PMID 39250515 · Hepatology · 2025-Apr-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic Pylorus-preserving Gastrectomy Versus Distal Gastrectomy for Early Gastric Cancer: A Multicenter Randomized Controlled Trial (KLASS-04). PMID 39219553 · Ann Surg · 2025-Apr-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Thoracic Epidural Analgesia Is Not Associated With Improved Survival After Pancreatic Surgery: Long-Term Follow-Up of the Randomized Controlled PAKMAN Trial. PMID 38335141 · Anesth Analg · 2025-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Psycho-oncology/Supportive Care in Head-Neck Cancers Patients Undergoing Radiation Therapy: A Randomized Controlled Trial. PMID 41426184 · South Asian J Cancer · 2025-Apr The trial is a randomized controlled trial in human oncology patients, but it does not meet the primary eligibility criteria. The intervention is psycho-oncology/palliative/supportive care referral (non-drug), and the primary endpoint is distress proportion (not a time-to-event endpoint like OS/PFS/DFS). Although survival endpoints are mentioned as having no significant difference, the report does not focus on or provide data for a primary/key secondary time-to-event efficacy endpoint suitable for Kaplan-Meier digitization. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Clinical efficacy of endocrinotherapy combined with Shenqi Pills on patients with hormone-sensitive prostate cancer]. PMID 40787962 · Zhonghua Nan Ke Xue · 2025-Apr The study is a randomized oncology trial in humans with a primary OS endpoint, but it is ineligible because the intervention combines a standard drug therapy with a Chinese herbal product (Shenqi Pills), which does not meet the strict 'drug-containing intervention' criterion for conventional drugs. Additionally, the trial phase is not explicitly reported as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metformin for recurrent colorectal polyp or adenoma prevention after polypectomy in patients without diabetes mellitus: a prospective study. PMID 40353629 · Neoplasma · 2025-Apr The study is a randomized, oncology, human, drug-intervention trial with original results, but it is excluded because the primary endpoint is not a time-to-event outcome (it is a binary proportion of adenoma recurrence at 1 year). There is no signal for OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. PMID 40337868 · Immunotherapy · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Japanese participant data from three gantenerumab trials in early Alzheimer's disease. PMID 40302041 · Alzheimers Dement · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cardiac myosin inhibition in hypertrophic cardiomyopathy: review of the evolving evidence base. PMID 40285342 · Expert Rev Cardiovasc Ther · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of colonoscopy screening on risks of colorectal cancer and related death: instrumental variable estimation of per-protocol effects. PMID 40278966 · Eur J Epidemiol · 2025-Apr The study is an oncology randomized trial (NordICC) evaluating colonoscopy screening for colorectal cancer prevention, with cancer incidence and mortality as primary endpoints. While it meets criteria for being oncology, human, randomized, and an original result, it does not contain a drug intervention (colonoscopy is a procedural/screening intervention, not a drug). Therefore, it fails the drug-intervention criterion and is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT study. PMID 40271888 · Alzheimers Dement · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer: A Phase II Non-Randomized Trial on Safety and Efficacy. PMID 40268743 · Cancer Invest · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cost-Effectiveness of Oral Levofloxacin Versus Amoxicillin-Clavulanate/Ciprofloxacin for Outpatient Management of Low-Risk Febrile Neutropenia in Children With Cancer in Egypt. PMID 40267379 · JCO Glob Oncol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Three-field vs two-field lymphadenectomy in thoracic ESCC patients: a multicenter randomized study (NST 1503). PMID 40265094 · J Natl Cancer Cent · 2025-Apr The study is an oncology randomized trial with time-to-event endpoints (OS, DFS) and reports original results. However, the intervention is purely surgical (lymphadenectomy techniques) and does not involve a drug-containing intervention, which is a required criterion for eligibility. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata or abstract text. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs. PMID 40265093 · J Natl Cancer Cent · 2025-Apr The record describes a methodological study validating a surrogate endpoint (PFS36 for OS) by analyzing aggregated data from multiple existing Phase III radiotherapy trials. It is not an original result report from a single randomized trial with a drug-containing intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials. PMID 40260308 · Crohns Colitis 360 · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Fixed-dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Black Participants with Moderate to Severe Acne. PMID 40256338 · J Clin Aesthet Dermatol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of a Single Preventive Intravenous Dose of Ketorolac and Paracetamol on Reducing Postoperative Pain in Septorhinoplasty Patients: Double-Blind Randomized Clinical Trial. PMID 40255229 · Iran J Med Sci · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial. PMID 40247887 · EClinicalMedicine · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial. PMID 40242562 · EClinicalMedicine · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. PMID 40241307 · Eur J Neurol · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial. PMID 40230305 · Health Technol Assess · 2025-Apr The record is a prospective prognostic model study in colorectal cancer, not a randomized drug intervention trial. It is an observational cohort evaluating biomarkers and imaging for prognosis, lacking randomization, a drug intervention, and a therapeutic efficacy endpoint. The deterministic review correctly flagged unclear Phase III evidence, and deeper analysis confirms ineligibility based on core criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice. PMID 40230191 · Pharmacol Res Perspect · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Symptom Attribution, Help Seeking and Willingness to Undergo Diagnostic Investigations for Bowel Cancer Symptoms in People With Anxiety and/or Depression-A Vignette Study. PMID 40220329 · Psychooncology · 2025-Apr The study is a randomized vignette study investigating symptom attribution, help-seeking, and willingness to undergo diagnostic tests for bowel cancer symptoms in people with anxiety/depression. It is an oncology-related human study but lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). It is not a Phase III/IIIb or Phase II/III drug efficacy trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |